FIELD: medicine.
SUBSTANCE: vaccine contains M2 protein ectodomain, a molecular adjuvant and a buffer solution taken in effective amounts. The M2 protein ectodomain is expressed by recombinant pseudoadenovirus particles based on a human adenovirus genome of serotype five in an individual's body in the form of a fusion protein consisting of four sequential M2 protein ectodomains of avian influenza type A and TLR 5 activator - flagellin Salmonella enterica serovar Dublin. As a molecular adjuvant, it contains TLR-4 activator - a herbal acid peptidoglycane having a molecular weight from 1000 to 40000 kDa.
EFFECT: invention is non-toxic and may be used for clinical applications in a human individual.
3 cl, 15 dwg, 5 tbl, 9 ex
